Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $115.00 short call and a strike $125.00 long call offers a potential 10.62% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $115.00 by expiration. The full premium credit of $0.96 would be kept by the premium seller. The risk of $9.04 would be incurred if the stock rose above the $125.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 24.3 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
Fri, 21 Dec 2018 14:31:02 +0000
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
Fri, 21 Dec 2018 14:13:02 +0000
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Lilly's Shares Rise on Robust 2019 View, Dividend Hike
Thu, 20 Dec 2018 20:50:08 +0000
Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.
Supernus Pharma's ADHD drug meets main goal in study on adolescents
Thu, 20 Dec 2018 15:57:34 +0000
Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors. At daily doses of 200 mg and 400 mg, the drug, SPN-812, showed statistical significance in improvement in symptoms such as hyperactivity and lack of attention among 12-17 year olds, Supernus said. SPN-812 is a non-stimulant and belongs to the same class of medicines as Eli Lilly and Co's Strattera and Shire Plc's Intuniv.
Allergan Drops, Stops Textured Breast Implant Sales in Europe
Thu, 20 Dec 2018 15:18:03 +0000
Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.
Also on Market Tamer…
Follow Us on Facebook